PA
SANA icon

Parallel Advisors’s Sana Biotechnology SANA Stock Holding History

Parallel Advisors’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-67
Closed -$113 – 3685
2025
Q1 		$113 Sell
67
-113
-63% -$316 ﹤0.01% 3432
2024
Q4 		$293 Buy
+180
New +$537 ﹤0.01% 3320
2023
Q4 		– Sell
-27
Closed -$104 – 3447
2023
Q3 		$104 Hold
27
– – ﹤0.01% 3279
2023
Q2 		$161 Buy
+27
New +$156 ﹤0.01% 3258

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Parallel Advisors's SANA Position: Q2 2025 in Review

Parallel Advisors sold out of Sana Biotechnology (SANA) in Q2 2025, closing a stake of 67 shares — an estimated $113 sold.

Parallel Advisors first reported a position in SANA in Q2 2023 and held it in 4 quarters. The position peaked at $293 in Q4 2024. 155 funds tracked by Wall St. Rank hold SANA as of Q2 2025.

  • Parallel Advisors reported no remaining Sana Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Parallel Advisors sold 67 Sana Biotechnology shares in Q2 2025, an estimated $113.
  • Parallel Advisors first reported a position in Sana Biotechnology in Q2 2023 and held it in 4 quarters.
  • Parallel Advisors's Sana Biotechnology position peaked at $293 in Q4 2024.
  • 155 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2025.

Based on Parallel Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.